Scientists from Norway have discovered a promising new approach to fighting antibiotic-resistant bacteria, according to research published in Nature Communications. The breakthrough centers on naturally occurring bacterial toxins that could potentially serve as alternatives to broad-spectrum antibiotics in treating dangerous infections.
A research team led by professors Ørjan Samuelsen from the University Hospital of North Norway, Jukka Corander from the University of Oslo, and Pål J. Johnsen from The Arctic University of Norway conducted an extensive genetic analysis of E. coli bacteria, which is globally the most common cause of urinary tract and bloodstream infections.
Using advanced sequencing technology, the scientists examined the complete chromosomes and plasmids, circular strands of DNA that can move between bacterial cells, in 2,000 samples from Norwegian patients with invasive infections. This represents the most comprehensive and detailed investigation of E. coli’s genetic material to date.
The researchers mapped the distribution of E. coli plasmids containing genes that produce toxins capable of eliminating closely related bacteria. Of twelve different toxins identified, one variant demonstrated particularly significant effectiveness.
In laboratory tests, the team cultivated several types of multidrug-resistant E. coli in petri dishes and applied the toxin produced by bacterial strains with a specific type of plasmid. The results showed that the toxin successfully killed the antibiotic-resistant bacteria.
This discovery could lead to new treatment approaches for infections that have become resistant to conventional antibiotics. The researchers envision developing personalized medicines that function like “precision-guided missiles” targeting specific harmful bacteria while preserving beneficial microbes.
Current broad-spectrum antibiotics often eliminate both harmful and beneficial bacteria indiscriminately. The researchers theorize that their approach could allow less harmful bacterial strains to outcompete more dangerous variants, potentially slowing the spread of difficult-to-treat infections.
The threat of antibiotic resistance is particularly serious with E. coli, as some variants have developed resistance to most available antibiotics. This limits treatment options to “last resort” medications, which doctors try to avoid using to prevent bacteria from developing resistance to these final options as well.
Without effective antibiotics, even initially mild urinary tract infections can become serious threats to patients with weakened immune systems, such as the elderly and cancer patients.
The research team hopes to extend their testing to Klebsiella pneumoniae, another dangerous bacterium that can cause pneumonia, meningitis, urinary tract infections, and blood and liver infections. The World Health Organization has classified certain antibiotic-resistant variants of Klebsiella as a serious threat to public health.
For this personalized medicine approach to work effectively, improved diagnostic capabilities will be needed so doctors can identify specific bacterial variants and prescribe the appropriate targeted treatment.
The study, conducted in collaboration with the Wellcome Sanger Institute and various Norwegian hospitals, has also resulted in a detailed overview of E. coli genetic variation that will serve as an important resource for future bacterial genetics and microbiology research.
Commenting on this article, the nation’s leading E. coli lawyer said, “This breakthrough could revolutionize how we address foodborne illness outbreaks caused by antibiotic-resistant E. coli strains, potentially saving lives when conventional treatments fail.”
